ME02935B - Vezujući domen bakterijske atp sintaze - Google Patents
Vezujući domen bakterijske atp sintazeInfo
- Publication number
- ME02935B ME02935B MEP-2017-214A MEP21417A ME02935B ME 02935 B ME02935 B ME 02935B ME P21417 A MEP21417 A ME P21417A ME 02935 B ME02935 B ME 02935B
- Authority
- ME
- Montenegro
- Prior art keywords
- amino acids
- dimensional structure
- mutated
- atpe
- test compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Claims (14)
1. Izolovan mutiran atpE protein koji obuhvata polipeptidnu sekvencu izabranu od SEQ ID NO O l koja obuhvata barem jednu tačkastu mutaciju koja se nalazi na bilo kom vezu jućem mestu ATPaze koje se nalazi između aminokiselina 14 do 34 ili između aminokiselina 54 do 69, i SEQ ID NO 03 koja obuhvata barem jednu tačkastu mutaciju koja se nalazi na bilo kojoj aminokiselini 20 do 40, ili ili aminokiselinama 60 do 75, gde navedeni protein indukuje rezistenciju na anti-mikrobsko jedinjenje DARQ J sa Slike l.
2. Izolovan mutiran atpE protein prema patentnom zahtevu l koji obuhvata polipeptidnu sekvencu izabranu iz grupe koju čine SEQ ID NO O 1 koj i obuhvata barem jednu tačkastu mutaciju koja se nalazi na aminokiselini 28 ili aminokiselini 63.
3. Izolovan mutiran atpE protein prema patentnom zahtevu l ili 2, izabran od Mtb_R kako je prikazano u SEQ ID No. 2, Msm R09 kako je prikazano u SEQ ID No.4, Ms m_ Rl O kako je prikazano u SEQ ID No.5.
4. Primena polipeptida prema bilo kom patentnom zahtevu od l do 3 u postupku za identifikovanje jedinjenja koja interakuju saFo delom ATPaze i za njihov potencijal kao antimikrobna jedin jenja.
5. Postupak procene potencijalnog test jedin jenja da interakuje sa atp E proteinom, gde navedeni postupak obuhvata; -tehnike molekularnog modeliranja za generisanje trodimenzionalne strukture mesta vezivanja prema bilo kom patentnom zahtevu od l do 3; - upotreba računskih sredstava za obavljanje operacije uklapanja između test jedinjenja i trodimenzionalne strukture mesta vezivanja; i - analiziranje rezultata pomenute operacije uklapanja za kvantifikaciju udruživanja test jedin jenja sa trodimenzionalnom strukturom mesta vezivanja.
6. Postupak prema patentnom zahtevu 5 gde je trodimenzionalna struktura generisana barem sa aminokiselinama Ala24, Gly27, Phe53, Va157, Gly58, Glu61, Tyr64 i Phe65 jedne C podjedinice i aminokiselinama Ser182, Leu183, Leu185, i Arg186 jedne A podjedinice, koristeći atomske koordinate bilo koje od Tabela 3, 4 ili 5 ili homologne strukturne koordinate koje sadrže koren srednjeg kvadratnog odstupanja ne-vodoničnih atoma od manje od oko 1,5A
7. Postupak prema patentnom zahtevu 5 gde je trodimenzionalna struktura generisana koristeći atomske koordinate ili aminokiseline Ala21, Gly25 od A Lanca bilo koje od Tabela 3, 4 ili 5; aminokiseline Ala24, Gly27, Phe53, Phe54, Val57, Gly58, Glu61 , Tyr64, Phe65 od K Lanca bilo koje od Tabela 3, 4 ili 5; aminokiseline Met17, Gly19 GJ20, AJa21, Ile22, Gly23, Ala24, GJy25, Ile26, Gly27, Asp28, Gly29, Ala31, Phe53, Thr56, VaJI 7, Gly58, Leu59 Val60, Glu61, Ala62, Ala63/Pro63, Tyr64, Phe65 od L Lanca bilo koje od Tabela 3, 4 ili 5; i ili aminokiseline Ser182, Leu 183, Leu185, i Arg186 od M Lanca bilo koje od Tabela 3, 4 ili 5.
8. Izolovanu sekvencu nukleinske kiseline koja kodira izolovan mutiran atpE protein prema bilo kom patentnom zahtevu od l do 3.
9.Vektor koji obuhvata sekvencu nukleinske kiseline prema patentnom zahtevu 8.
10.Ćelija domaćin koja nosi vektor prema patentnom zahtevu 9
11. Postupak za identifikovanje anti-mikrobnog jedin jenja, gde navedeni postupak obuhvata a) dovođenje u dodir ćelije koja eksprimira atpE protein sa test jedin jen jem pod fiziološkim uslovima, i b) određivanje da li testjedinjenje interakuje sa atpE proteinom gde je atpE protein mutiran atpE protein prema bilo kom patentnom zahtevu od 1 do 3.
12. Postupak za procenu potencijalnog test jedin jenja da interakuje sa mutiranim atpE proteinom prema bilo kom patentnom zahtevu od 1 do 3, gde navedeni postupak obuhvata;a) tehnike molekularnog modeliranja za generisanje trodimenzionalne strukture mutiranog atpE proteina prema bilo kom patentnom zahtevu od l do 3, b) upotreba računskih sredstava za obavljanje operacije uklapanja između test jedinjenja i trodimenzionalne strukture mutiranog atpE proteina prema patentnim zahtevima l do 3, i e) analiziranje rezultata pomenute operacije uklapanja za kvantifikaciju udruživanja test jedinjenja sa trodimenzionalnom strukturom mutiranog atpE protein prema patentnim zahtevima 1 do 3.
13. Postupak prema patentnom zahtevu 12 gde je trodimenzionalna struktura atpE proteina generisana koristeći atomske koordinate Ile28, Glu61 i Ile63 od E. coli (Protein Database l QO l) +/- koren srednje srednje kvadratne devijacije kičme atoma navedenih aminokiselina od ne više od l OA.
14. Postupak prema patentnom zahtevu 12 gde je trodimenzionalna struktura atpE proteina generisana koristeći atomske koordinate prema Tabelama 6 ili 7 +/- koren srednje srednje kvadratne devijacije kičme atoma navedenih aminokiselina od ne više od l ,5A.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04104720 | 2004-09-28 | ||
| PCT/EP2005/054893 WO2006035051A1 (en) | 2004-09-28 | 2005-09-28 | A bacterial atp synthase binding domain |
| EP05794520.6A EP1797115B1 (en) | 2004-09-28 | 2005-09-28 | A bacterial atp synthase binding domain |
| US201861620500P | 2018-01-10 | 2018-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02935B true ME02935B (me) | 2018-04-20 |
Family
ID=38965678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-214A ME02935B (me) | 2004-09-28 | 2005-09-28 | Vezujući domen bakterijske atp sintaze |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8088891B2 (me) |
| EP (1) | EP1797115B1 (me) |
| JP (2) | JP2008515395A (me) |
| KR (1) | KR101539021B1 (me) |
| CN (1) | CN101065397B (me) |
| AU (2) | AU2005288848A1 (me) |
| CA (1) | CA2579971C (me) |
| CY (1) | CY1119568T1 (me) |
| DK (1) | DK1797115T3 (me) |
| ES (1) | ES2636980T3 (me) |
| HR (1) | HRP20171388T1 (me) |
| HU (1) | HUE033609T2 (me) |
| IL (1) | IL182185A (me) |
| LT (1) | LT1797115T (me) |
| ME (1) | ME02935B (me) |
| NO (1) | NO342699B1 (me) |
| NZ (1) | NZ553693A (me) |
| PL (1) | PL1797115T3 (me) |
| PT (1) | PT1797115T (me) |
| RS (1) | RS56357B1 (me) |
| RU (1) | RU2418001C2 (me) |
| SI (1) | SI1797115T1 (me) |
| WO (1) | WO2006035051A1 (me) |
| ZA (1) | ZA200702540B (me) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2440736A (en) * | 2006-08-10 | 2008-02-13 | Medical Res Council | Crystals of mutant p53 polypeptidtes |
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2685B1 (en) | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| JO3271B1 (ar) | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| ES2607879T3 (es) | 2012-04-27 | 2017-04-04 | Janssen Pharmaceutica N.V. | Derivados de quinolina antibacterianos |
| US8454434B1 (en) * | 2012-06-15 | 2013-06-04 | Igt | Gaming system and method for providing an offer and acceptance game with progressive awards associated with a quantity of progressive tokens |
| JP5580383B2 (ja) | 2012-10-05 | 2014-08-27 | 株式会社 資生堂 | 美容機器及び通電方法及び記録媒体 |
| KR101522087B1 (ko) * | 2013-06-19 | 2015-05-28 | 삼성에스디에스 주식회사 | 미스매치를 고려한 염기 서열 정렬 시스템 및 방법 |
| CN110373399B (zh) * | 2019-07-09 | 2021-05-28 | 湖南省植物保护研究所 | 一种沼泽红假单胞菌Atps2蛋白及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE146783T1 (de) | 1991-11-01 | 1997-01-15 | Upjohn Co | Substituierte aryl- und heteroaryl- phenyloxazolidinone |
| US6583266B1 (en) * | 1993-08-19 | 2003-06-24 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics |
| RU2245719C2 (ru) * | 2000-03-28 | 2005-02-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Тимолсодержащая композиция, полезная для лечения устойчивых к лекарственным средствам бактериальных инфекций |
| WO2001089531A1 (en) * | 2000-05-19 | 2001-11-29 | Genetics Institute, Llc | Crystal structures of p- selectin,ep0105895-selectin complexes, and uses thereof |
| JP4122216B2 (ja) * | 2000-09-19 | 2008-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＧＳＫ−３βタンパク質の特徴づけおよびその使用方法 |
| AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| PT1443937E (pt) | 2001-11-13 | 2008-09-23 | Ortho Mcneil Janssen Pharm | 1,4-benzodiazepinas substituídas e as suas utilizações para o tratamento de cancro |
| ATE463482T1 (de) * | 2002-07-25 | 2010-04-15 | Janssen Pharmaceutica Nv | Chinolinderivate und deren verwendung als mycobakterielle inhibitoren |
| AU2002951853A0 (en) * | 2002-10-04 | 2002-10-24 | Commonwealth Scientific And Industrial Research Organisation | Crystal structure of erbb2 and uses thereof |
-
2005
- 2005-09-28 PL PL05794520T patent/PL1797115T3/pl unknown
- 2005-09-28 KR KR1020077009488A patent/KR101539021B1/ko not_active Expired - Fee Related
- 2005-09-28 CN CN200580040762.3A patent/CN101065397B/zh not_active Expired - Fee Related
- 2005-09-28 JP JP2007532910A patent/JP2008515395A/ja not_active Withdrawn
- 2005-09-28 ES ES05794520.6T patent/ES2636980T3/es active Active
- 2005-09-28 LT LTEP05794520.6T patent/LT1797115T/lt unknown
- 2005-09-28 HR HRP20171388TT patent/HRP20171388T1/hr unknown
- 2005-09-28 SI SI200532172T patent/SI1797115T1/sl unknown
- 2005-09-28 HU HUE05794520A patent/HUE033609T2/en unknown
- 2005-09-28 AU AU2005288848A patent/AU2005288848A1/en not_active Abandoned
- 2005-09-28 WO PCT/EP2005/054893 patent/WO2006035051A1/en not_active Ceased
- 2005-09-28 EP EP05794520.6A patent/EP1797115B1/en not_active Expired - Lifetime
- 2005-09-28 ME MEP-2017-214A patent/ME02935B/me unknown
- 2005-09-28 CA CA2579971A patent/CA2579971C/en not_active Expired - Lifetime
- 2005-09-28 RU RU2007116144/10A patent/RU2418001C2/ru active
- 2005-09-28 DK DK05794520.6T patent/DK1797115T3/en active
- 2005-09-28 PT PT57945206T patent/PT1797115T/pt unknown
- 2005-09-28 US US11/576,023 patent/US8088891B2/en not_active Expired - Fee Related
- 2005-09-28 NZ NZ553693A patent/NZ553693A/xx not_active IP Right Cessation
- 2005-09-28 RS RS20170911A patent/RS56357B1/sr unknown
-
2007
- 2007-03-26 IL IL182185A patent/IL182185A/en active IP Right Grant
- 2007-03-27 ZA ZA200702540A patent/ZA200702540B/xx unknown
- 2007-04-30 NO NO20072237A patent/NO342699B1/no unknown
-
2011
- 2011-11-29 US US13/306,255 patent/US8378085B2/en not_active Expired - Fee Related
-
2012
- 2012-05-11 JP JP2012109892A patent/JP5837852B2/ja not_active Expired - Fee Related
- 2012-08-16 AU AU2012216368A patent/AU2012216368B2/en not_active Ceased
-
2017
- 2017-09-20 CY CY20171100997T patent/CY1119568T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02935B (me) | Vezujući domen bakterijske atp sintaze | |
| Shelest | Transcription factors in fungi | |
| Lehembre et al. | Soil metatranscriptomics for mining eukaryotic heavy metal resistance genes | |
| Shao et al. | Long-term evolution of nucleotide-binding site-leucine-rich repeat genes: understanding gained from and beyond the legume family | |
| Andolfo et al. | Genetic variability and evolutionary diversification of membrane ABC transporters in plants | |
| Li et al. | Phylogenetics of Chondrichthyes and the problem of rooting phylogenies with distant outgroups | |
| Tenhaken et al. | DCD–a novel plant specific domain in proteins involved in development and programmed cell death | |
| Ruytinx et al. | Identification, evolution and functional characterization of two Zn CDF‐family transporters of the ectomycorrhizal fungus Suillus luteus | |
| CN105676814A (zh) | 基于sfla-svm的数字化水岛在线加药控制方法 | |
| Flores-Téllez et al. | Insights into the conservation and diversification of the molecular functions of YTHDF proteins | |
| Zhou et al. | Loss of LaMATE impairs isoflavonoid release from cluster roots of phosphorus‐deficient white lupin | |
| Zhang et al. | Genome-wide identification and expression profiling of the copper transporter gene family in Populus trichocarpa | |
| CN105354441A (zh) | 构建植物蛋白质互作网络的方法 | |
| Yan et al. | Characterization of a novel arsenite long‐distance transporter from arsenic hyperaccumulator fern Pteris vittata | |
| Raes et al. | Gene duplication, the evolution of novel gene functions, and detecting functional divergence | |
| Zhang et al. | PPR proteins in the tea plant (Camellia sinensis) and their potential roles in the leaf color changes | |
| Barre-Villeneuve et al. | The unique dual targeting of AGO1 by two types of PRMT enzymes promotes phasiRNA loading in Arabidopsis thaliana | |
| Jia et al. | Integrated analysis of protein abundance, transcript level, and tissue diversity to reveal developmental regulation of maize | |
| Kushwah et al. | Elucidating the zinc-binding proteome of Fusarium oxysporum f. sp. lycopersici with particular emphasis on zinc-binding effector proteins | |
| Braun | Innovation from reduction: gene loss, domain loss and sequence divergence in genome evolution | |
| de Barsy et al. | Functional genomics of intracellular bacteria | |
| Singh et al. | Dual localization of JA receptor, CaCOI2, explains JA perception dynamics in chickpea | |
| Zamani et al. | Determining the Protein Structure and Evaluating the Gene Expression Level of Tup1 from Zymoseptoria tritici. | |
| Sharma et al. | Bioinformatics resources and approaches for the interaction of Oryza sativa and Magnaporthe oryzae pathosystem | |
| KR20200066465A (ko) | 수은 센싱 미생물 진단키트 및 이의 제조방법 |